Searched for
ADVAIR
Hot Stocks: Brokerages on UltraTech Cements, GAIL India, and CiplaGoldman Sachs maintained its buy rating on UltraTech Cements with a target price of Rs 8500. The global investment bank is seeing improved ...03 Mar, 2023, 10.55 AM IST- Cipla stocks dive to 7-month low; here’s why bears are ruling the counterIf they are minor in nature, then it is unlikely to hurt sales from the unit. However, if the regulator found major deviations from good ma...20 Feb, 2023, 11.29 AM IST
- Buy Cipla, target price Rs 1120: Centrum BrokingCipla Ltd., incorporated in the year 1935, is a Large Cap company (having a market cap of Rs 72586.73 Crore) operating in Pharmaceuticals s...29 Oct, 2021, 10.19 AM IST
- Covid crisis has given us an opportunity to re-imagine our business: CiplaNew respiratory portfolio could sustainably grow Cipla’s business and we are looking forward to that over the next two to three years.11 Aug, 2020, 02.40 PM IST
- Cipla submits application with USFDA for generic version of asthma drugDrug major Cipla on Monday said it has submitted an application with the US health regulator for a generic version of GSK's Advair Diskus, ...18 May, 2020, 10.51 AM IST
- Cipla jumps 8% on completing Phase-3 clinical study of asthma drugThe generic would be used for treatment of asthma and chronic obstructive pulmonary disease.03 Apr, 2020, 03.58 PM IST
- Cipla’s India revenue grows 13%: Key Q3 takeawaysTotal revenue increased 9.06 per cent to Rs 4,371 crore during the quarter under review.05 Feb, 2020, 09.02 PM IST
- Buy Cipla, target Rs 570: HSBCHSBC expects earnings led recovery largely in the second half of FY17.21 Jun, 2016, 12.50 PM IST
- The colour purple that has left drug makers like Dr Reddy's Laboratories paleThe reference here has nothing to do with the Pulitzer-winning book of Alice Walker, but the actual colour that has pushed big pharma to pu...14 Nov, 2015, 02.53 PM IST
- Cipla slips as rival Mylan launches generic Seretide in UK's $400-mn anti-asthma drug marketShares of Cipla fell nearly 3 per cent intraday after rivals Mylan launched first generic version of anti-asthma drug Seretide.09 Jun, 2015, 06.32 PM IST
- Lupin ties up with Poland-based firm for generic asthama drugLupin has set up a dedicated centre of excellence for inhalation research in Florida after having hired top notch inhalation scientists las...17 Feb, 2015, 03.46 PM IST
- GlaxoSmithKline confirms "hundreds" of US job cuts as market gets tougherMany of the jobs lost will be from GSK's Research Triangle Park site as drug research is consolidated in Philadelphia and in Stevenage, nea...04 Dec, 2014, 03.49 AM IST
- Cipla launches combination inhalers in Germany and Sweeden; stocks touch all time high, may trigger reratingThe maiden launch increases the possibility and visibility of subsequent launches of the company’s inhalers in other countries.04 Sep, 2014, 03.32 AM IST
- Brokerages raise Cipla's target price post inhaler launchAnalysts at Emkay Global Financial Services are of the view that the launch will have a strong positive impact on the company’s margins.02 Sep, 2014, 11.44 AM IST
- Lupin to file new drug application for GSK’s $8 bn blockbuster inhaler AdvairMumbai-based drug maker Lupin Pharma will file an Abbreviated New Drug Application for GSK’s $8-billion dry powder inhaler Advair, said Vin...26 Jul, 2012, 11.49 AM IST
- Brokers' Call: ONGC, DRL, Cipla and Coal IndiaWe have compiled stock views and recommendations from various agencies on ONGC, Dr Reddy's, Cipla and Coal India.06 Mar, 2012, 10.36 AM IST
- RBS recommends a 'Buy' rating on CiplaRBS has recommended a 'Buy' rating on Cipla with a target price of 360.06 Mar, 2012, 05.23 AM IST
Load More
